Christina Yee, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Desensitization, Immunologic | 6 | 2020 | 556 | 1.400 |
Why?
|
| Urticaria | 2 | 2019 | 150 | 1.150 |
Why?
|
| Allergens | 3 | 2018 | 1432 | 1.020 |
Why?
|
| Clindamycin | 1 | 2018 | 139 | 0.590 |
Why?
|
| Anti-Allergic Agents | 1 | 2018 | 153 | 0.570 |
Why?
|
| Acetaminophen | 1 | 2020 | 554 | 0.530 |
Why?
|
| Anaphylaxis | 3 | 2018 | 757 | 0.520 |
Why?
|
| Peanut Hypersensitivity | 1 | 2018 | 219 | 0.500 |
Why?
|
| Cold Temperature | 1 | 2018 | 785 | 0.480 |
Why?
|
| Drug Hypersensitivity | 2 | 2020 | 917 | 0.420 |
Why?
|
| Homozygote | 2 | 2021 | 1776 | 0.390 |
Why?
|
| Cytoskeleton | 1 | 2015 | 1170 | 0.360 |
Why?
|
| Protein Multimerization | 1 | 2015 | 983 | 0.350 |
Why?
|
| Virus Diseases | 2 | 2015 | 718 | 0.350 |
Why?
|
| Microfilament Proteins | 1 | 2015 | 1134 | 0.350 |
Why?
|
| Food Hypersensitivity | 1 | 2016 | 729 | 0.300 |
Why?
|
| Neutrophils | 1 | 2020 | 3767 | 0.290 |
Why?
|
| Trans-Activators | 3 | 2005 | 2856 | 0.260 |
Why?
|
| Cathepsin E | 1 | 2004 | 3 | 0.240 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2005 | 223 | 0.240 |
Why?
|
| Nuclear Proteins | 4 | 2015 | 5796 | 0.230 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2005 | 1435 | 0.230 |
Why?
|
| Respiratory Burst | 1 | 2020 | 110 | 0.180 |
Why?
|
| Rhodamines | 1 | 2020 | 178 | 0.170 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2020 | 50 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 7407 | 0.170 |
Why?
|
| Interleukin-10 | 1 | 2005 | 1175 | 0.160 |
Why?
|
| Administration, Oral | 2 | 2018 | 4021 | 0.160 |
Why?
|
| Glycocalyx | 1 | 2020 | 97 | 0.160 |
Why?
|
| Up-Regulation | 2 | 2005 | 4124 | 0.160 |
Why?
|
| Bee Venoms | 1 | 2018 | 23 | 0.160 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2018 | 1802 | 0.160 |
Why?
|
| GTPase-Activating Proteins | 1 | 2021 | 471 | 0.150 |
Why?
|
| Insect Bites and Stings | 1 | 2018 | 71 | 0.150 |
Why?
|
| Indolizines | 1 | 1997 | 30 | 0.150 |
Why?
|
| Cefazolin | 1 | 2018 | 94 | 0.150 |
Why?
|
| Mutation | 3 | 2018 | 30052 | 0.140 |
Why?
|
| Skin Tests | 1 | 2018 | 637 | 0.130 |
Why?
|
| Warts | 1 | 2015 | 66 | 0.130 |
Why?
|
| Carboplatin | 1 | 1998 | 794 | 0.130 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2018 | 347 | 0.130 |
Why?
|
| Cell Degranulation | 1 | 2015 | 277 | 0.120 |
Why?
|
| Pedigree | 3 | 2021 | 4542 | 0.120 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2015 | 173 | 0.120 |
Why?
|
| Pruritus | 1 | 2018 | 380 | 0.120 |
Why?
|
| Dendritic Cells | 2 | 2005 | 2747 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2018 | 549 | 0.110 |
Why?
|
| Child | 9 | 2021 | 80153 | 0.110 |
Why?
|
| Edema | 1 | 2018 | 766 | 0.110 |
Why?
|
| Withholding Treatment | 1 | 2018 | 617 | 0.110 |
Why?
|
| Frameshift Mutation | 1 | 2015 | 392 | 0.110 |
Why?
|
| Lymphopenia | 1 | 2015 | 281 | 0.110 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 778 | 0.110 |
Why?
|
| Exanthema | 1 | 2018 | 503 | 0.110 |
Why?
|
| Cell Death | 1 | 1998 | 1678 | 0.110 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2015 | 227 | 0.110 |
Why?
|
| Flow Cytometry | 3 | 2020 | 5869 | 0.100 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2021 | 918 | 0.100 |
Why?
|
| Immunoglobulins | 1 | 2015 | 853 | 0.100 |
Why?
|
| Cell Survival | 3 | 2015 | 5791 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1089 | 0.100 |
Why?
|
| Immunoglobulin E | 1 | 2018 | 1502 | 0.100 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2013 | 168 | 0.100 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2015 | 547 | 0.090 |
Why?
|
| Siblings | 1 | 2015 | 825 | 0.090 |
Why?
|
| Calcium Channels | 1 | 2015 | 620 | 0.090 |
Why?
|
| Autoantigens | 1 | 2015 | 891 | 0.090 |
Why?
|
| Cell Cycle | 1 | 1998 | 2932 | 0.090 |
Why?
|
| Protein Transport | 1 | 2015 | 1967 | 0.080 |
Why?
|
| Antigen Presentation | 2 | 2005 | 1251 | 0.080 |
Why?
|
| Actins | 1 | 2015 | 2050 | 0.080 |
Why?
|
| Autoantibodies | 2 | 2015 | 2116 | 0.070 |
Why?
|
| Adolescent | 5 | 2018 | 88319 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2005 | 2919 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2020 | 3548 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2015 | 10194 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 4111 | 0.070 |
Why?
|
| Cytokines | 3 | 2015 | 7396 | 0.070 |
Why?
|
| Skin Diseases | 1 | 2015 | 1094 | 0.070 |
Why?
|
| Humans | 21 | 2021 | 761504 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 8529 | 0.070 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 2416 | 0.070 |
Why?
|
| Immunoconjugates | 1 | 2013 | 954 | 0.060 |
Why?
|
| Thrombosis | 1 | 2020 | 2942 | 0.060 |
Why?
|
| Enzyme Repression | 1 | 2004 | 30 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2015 | 4141 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2015 | 4369 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 3080 | 0.060 |
Why?
|
| Transfection | 3 | 2015 | 5774 | 0.060 |
Why?
|
| Enzyme Precursors | 1 | 2004 | 170 | 0.060 |
Why?
|
| Vaccinia virus | 1 | 2005 | 331 | 0.060 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2004 | 123 | 0.060 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2005 | 239 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2020 | 42230 | 0.050 |
Why?
|
| Female | 10 | 2021 | 392644 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 2244 | 0.050 |
Why?
|
| Mice | 6 | 2021 | 81525 | 0.050 |
Why?
|
| Male | 13 | 2021 | 360804 | 0.050 |
Why?
|
| Dextrans | 1 | 2005 | 574 | 0.050 |
Why?
|
| Cell Line, Transformed | 1 | 2004 | 867 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2018 | 4652 | 0.050 |
Why?
|
| Ovalbumin | 1 | 2004 | 677 | 0.050 |
Why?
|
| Retroviridae | 1 | 2005 | 850 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2014 | 14414 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 1999 | 6132 | 0.050 |
Why?
|
| Animals | 11 | 2021 | 168459 | 0.050 |
Why?
|
| Infant | 3 | 2020 | 36192 | 0.050 |
Why?
|
| Transduction, Genetic | 1 | 2005 | 903 | 0.050 |
Why?
|
| Disease Progression | 1 | 2018 | 13506 | 0.050 |
Why?
|
| Paclitaxel | 2 | 1999 | 1732 | 0.050 |
Why?
|
| Hypertension | 1 | 2021 | 8540 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 9606 | 0.050 |
Why?
|
| Prostatic Neoplasms | 3 | 1999 | 11118 | 0.050 |
Why?
|
| Myelin Proteolipid Protein | 1 | 2001 | 107 | 0.050 |
Why?
|
| Immunotherapy, Active | 1 | 2001 | 59 | 0.050 |
Why?
|
| Caspases | 2 | 2001 | 879 | 0.050 |
Why?
|
| Callithrix | 1 | 2001 | 94 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 15842 | 0.040 |
Why?
|
| Lymphocytosis | 1 | 2021 | 121 | 0.040 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2021 | 234 | 0.040 |
Why?
|
| CpG Islands | 1 | 2005 | 1230 | 0.040 |
Why?
|
| Leukocytosis | 1 | 2021 | 251 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 8002 | 0.040 |
Why?
|
| Immunodominant Epitopes | 1 | 2001 | 239 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 1997 | 6346 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2004 | 1062 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2004 | 1687 | 0.040 |
Why?
|
| Spleen | 1 | 2005 | 2295 | 0.040 |
Why?
|
| Bees | 1 | 2018 | 46 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2018 | 26198 | 0.040 |
Why?
|
| Dendrites | 1 | 2001 | 475 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 422 | 0.040 |
Why?
|
| Phenotype | 1 | 2015 | 16591 | 0.040 |
Why?
|
| S Phase | 1 | 1998 | 421 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2005 | 2416 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2005 | 2206 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2014 | 7856 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2020 | 80636 | 0.030 |
Why?
|
| Quality of Life | 1 | 2018 | 13367 | 0.030 |
Why?
|
| Time Factors | 1 | 2018 | 39967 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2014 | 11528 | 0.030 |
Why?
|
| Plasma | 1 | 2020 | 586 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2020 | 773 | 0.030 |
Why?
|
| Brugia malayi | 1 | 1995 | 5 | 0.030 |
Why?
|
| Wuchereria bancrofti | 1 | 1995 | 20 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2005 | 22169 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2005 | 5789 | 0.030 |
Why?
|
| Filariasis | 1 | 1995 | 26 | 0.030 |
Why?
|
| HeLa Cells | 2 | 1999 | 3093 | 0.030 |
Why?
|
| Cell Line | 3 | 2005 | 15601 | 0.030 |
Why?
|
| Antigens, Helminth | 1 | 1995 | 68 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1999 | 621 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2005 | 3688 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2015 | 23445 | 0.030 |
Why?
|
| Epinephrine | 1 | 2018 | 792 | 0.030 |
Why?
|
| Apoptosis | 3 | 2001 | 9486 | 0.030 |
Why?
|
| Necrosis | 1 | 1998 | 1611 | 0.030 |
Why?
|
| Ion Transport | 1 | 2015 | 319 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2015 | 817 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2018 | 64680 | 0.030 |
Why?
|
| Gene Expression | 2 | 2018 | 7581 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2015 | 1060 | 0.030 |
Why?
|
| Consanguinity | 1 | 2015 | 456 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 1870 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2015 | 1762 | 0.030 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2015 | 384 | 0.030 |
Why?
|
| Toll-Like Receptors | 1 | 2015 | 589 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 4511 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2018 | 1118 | 0.020 |
Why?
|
| Phagocytosis | 1 | 1997 | 1528 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2004 | 5112 | 0.020 |
Why?
|
| Lymphocyte Activation | 2 | 2018 | 5486 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2014 | 1646 | 0.020 |
Why?
|
| Adult | 4 | 2020 | 221177 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 1997 | 3595 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2005 | 18965 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2004 | 12795 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 2547 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2020 | 4431 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 16981 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 2645 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 1997 | 4915 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1998 | 2020 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2015 | 4278 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 2001 | 3220 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2015 | 1943 | 0.020 |
Why?
|
| Protein Binding | 1 | 2018 | 9351 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 6228 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2455 | 0.020 |
Why?
|
| Glutamate Decarboxylase | 1 | 2005 | 239 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2014 | 8320 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 1991 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 2005 | 964 | 0.010 |
Why?
|
| Rats | 1 | 1997 | 23742 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2001 | 364 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 18252 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 11076 | 0.010 |
Why?
|
| Cyclin B1 | 1 | 1999 | 58 | 0.010 |
Why?
|
| Cyclin B | 1 | 1999 | 104 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2015 | 10445 | 0.010 |
Why?
|
| Luciferases | 1 | 2001 | 714 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 1741 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2001 | 1379 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2001 | 10766 | 0.010 |
Why?
|
| Young Adult | 2 | 2015 | 59243 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 9177 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 2748 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2001 | 1699 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 6534 | 0.010 |
Why?
|
| Plasmids | 1 | 2001 | 2269 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2001 | 1036 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2001 | 1060 | 0.010 |
Why?
|
| Exons | 1 | 2001 | 2391 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 1756 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 12441 | 0.010 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1995 | 303 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 3792 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 4575 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2001 | 5035 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 4853 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2001 | 2490 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2005 | 4758 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2001 | 3734 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2001 | 2909 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2001 | 3442 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 13446 | 0.010 |
Why?
|
| Epitopes | 1 | 1995 | 2503 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 17635 | 0.000 |
Why?
|
| Cell Cycle Proteins | 1 | 1999 | 3448 | 0.000 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 4174 | 0.000 |
Why?
|
| DNA | 1 | 2001 | 7212 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 2001 | 7594 | 0.000 |
Why?
|
| Brain | 1 | 2001 | 27112 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2001 | 36426 | 0.000 |
Why?
|